Maverick Capital’s Novo Nordisk NVO Stock Holding History

Maverick Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.3M	Sell	1,653,872 -426,249	-20%	-$18.3M	0.7%	40
2026 Q1	$76.4M	Buy	+2,080,121	New	+$98.6M	0.88%	36
2024 Q3	–	Sell	-7,849	Closed	-$1.12M	–	295
2024 Q2	$1.12M	Buy	7,849 +5,744	+273%	+$761K	0.02%	206
2024 Q1	$270K	Buy	+2,105	New	+$251K	0.01%	362
2023 Q2	–	Sell	-4,312	Closed	-$343K	–	509
2023 Q1	$343K	Sell	4,312 -296	-6%	-$21K	0.01%	382
2022 Q4	$312K	Sell	4,608 -342	-7%	-$20.1K	0.01%	275
2022 Q3	$247K	Buy	+4,950	New	+$265K	0.01%	274
2021 Q1	–	Sell	-5,316	Closed	-$186K	–	825
2020 Q4	$186K	Sell	5,316 -12,550	-70%	-$434K	﹤0.01%	536
2020 Q3	$620K	Buy	+17,866	New	+$596K	0.01%	392

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Maverick Capital's NVO Position: Q2 2026 in Review

Maverick Capital reduced its Novo Nordisk (NVO) stake by 20% in Q2 2026, selling an estimated $18.3M and leaving 1,653,872 shares worth $79.3M. The position accounts for 0.7% of the portfolio, ranked #40.

Maverick Capital first reported a position in NVO in Q3 2020 and has held it in 9 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Maverick Capital held 1,653,872 shares of Novo Nordisk worth $79.3M as of Q2 2026.
Maverick Capital sold 426,249 Novo Nordisk shares in Q2 2026, an estimated $18.3M.
Novo Nordisk made up 0.7% of Maverick Capital's portfolio in Q2 2026, its #40 holding.
Maverick Capital first reported a position in Novo Nordisk in Q3 2020 and has held it in 9 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.